Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.
$CRBP
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/30/2024 | $85.00 | Outperform | Wedbush |
| 7/22/2024 | $80.00 | Buy | H.C. Wainwright |
| 6/26/2024 | $85.00 | Buy | B. Riley Securities |
| 6/3/2024 | $60.00 → $80.00 | Outperform | Oppenheimer |
| 5/13/2024 | $77.00 | Outperform | RBC Capital Mkts |
| 3/6/2024 | $4.00 → $46.00 | Hold → Buy | Jefferies |
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
Wedbush initiated coverage of Corbus Pharma with a rating of Outperform and set a new price target of $85.00
H.C. Wainwright resumed coverage of Corbus Pharma with a rating of Buy and set a new price target of $80.00
B. Riley Securities initiated coverage of Corbus Pharma with a rating of Buy and set a new price target of $85.00
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
3 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
144 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
CRB-913 brain levels are 15-fold lower than monlunabant in lean miceDose-response demonstrated for a range of 5 to 80 mg/kg/day achieving up to 38% weight loss in DIO miceSemaglutide treatment followed by its replacement with CRB-913 demonstrated continued weight loss in DIO miceSwitching from semaglutide to CRB-913 led to a doubling of fat loss in DIO mice NORWOOD, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company with a diversified portfolio, presents new pre-clinical data at Obesity Week 2024 further characterizing CRB-913, its highly peripherally restricted CB1 inverse agoni
NORWOOD, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the Guggenheim Securities Healthcare Innovation Conference to be held November 11-13, 2024 in Boston, MA. Guggenheim Securities Healthcare Innovation ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: November 12, 2024Time: 10:00 a.m. ETWebcast: Click here About Corbus Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to he
NORWOOD, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company with a diversified portfolio, announced today that it has completed enrollment of the dose escalation part of its bridging Phase 1 clinical trial of CRB-701 (SYS6002). The dose escalation part of this open label study (NCT06265727) is being conducted in the US and the UK. The three-part Phase 1 trial is evaluating the safety, pharmacokinetics and efficacy of CRB-701 in patients with advanced solid tumors associated with high Nectin-4 expression. The Part A dose escalation of the Phase 1 study is evaluating four predetermined dose
HC Wainwright & Co. analyst Andrew Fein reinstates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and announces $80 price target.
GAINERS: Green Growth Brands (OTC:GGBXF) shares closed up 9900.00% at $0.0001 Rocky Mountain High (OTC:RMHB) shares closed up 33.33% at $0.02 SOL Glb Inv (OTC:SOLCF) shares closed up 19.57% at $0.05 Affinor Growers (OTC:RSSFF) shares closed up 19.12% at $0.08 Pharmadrug (OTC:LMLLF) shares closed up 18.52% at $0.02 1933 Industries (OTC:TGIFF) shares closed up 8.23% at $0.01 Cansortium (OTC:CNTMF) shares closed up 7.14% at $0.15 CV Sciences (OTC:CVSI) shares closed up 7.12% at $0.06 CLS Holdings USA (OTC:CLSH) shares closed up 6.26% at $0.04 Cipher Pharmaceuticals (OTC:CPHRF) shares closed up 5.67% at $6.43 Body and Mind (OTC:BMMJ) shares closed up 5.40% at $0.03 OrganiGram Holdings (NASDAQ:O
GeneDx Holdings Corp. (NASDAQ:WGS) has made the biggest gains on the Russell 2000 Index in 2024 as the biotechnology company moves toward more comprehensive genetic testing. The Maryland-based company’s shares have soared 1,101% so far this year as of midday Thursday, according to Tradingview. Goldman Sachs analyst Matthew Sykes attributes much of GeneDX’s positive momentum to shifting its testing. The company went from panel-based tests, which look for variants in more than one gene, to exome/genome testing, which analyzes the bulk of a person’s DNA to find genetic variations. Also Read: GeneDx Stock Climbs After Better-Than-Expected Q1 Results, Raises FY24 Guidance “We remain o
NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee. "With this track record of success in both the pharma industry and on Wall Street, Winston has earned a well-deserved reputation for his leadership and financial acumen," said Alan F. Holmer, Chairman of the Corbus Board of Directors. "We are delighted to welcome someone of Winston's stature and expertise to our Board and we look forward to his insights and guidance." "Winston brings an e
NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company's Chief Medical Officer (CMO). In this role, Dr. Smethurst will lead the clinical development of the Company's investigational oncology drugs: CRB-701, a next generation Nectin-4 targeting antibody drug conjugate (ADC) developed in partnership with CSPC, and CRB-601, a TGFβ blocking monoclonal antibody targeting the integrin αvβ8. Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Company's h
NORWOOD, Mass., March 6, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced the appointment of Yong Ben, M.D., MBA, to the Company's Board of Directors. "Dr. Ben is a distinguished oncology researcher and pharma industry executive, with multiple drug approvals to his credit, and his appointment is a welcome addition to our Board," said Alan Holmer, Chairman of the Board of Directors of Corbus. "Our recent license agreement for CRB-701 has helped cement our position as a precision o
SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)